MOTS-c
A 16-amino acid peptide encoded within mitochondrial DNA - one of the first mitochondria-derived peptides ever discovered. Regulates glucose metabolism, activates AMPK, and mimics the metabolic effects of exercise at the cellular level. A defining longevity compound of 2026 research.
Medical Disclaimer: The information on this page is for educational and research purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
What Makes MOTS-c Unique
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) was discovered in 2015 by researchers at USC. It is one of the first peptides identified as being encoded within mitochondrial DNA -- a discovery that changed our understanding of how mitochondria communicate with the rest of the cell.
Mechanism of Action
- AMPK activation -- MOTS-c activates AMPK through a pathway independent of the AMP/ATP ratio, enabling metabolic adaptation even when cellular energy is not depleted
- Glucose regulation -- translocates to the nucleus under metabolic stress, regulating genes involved in glucose homeostasis and insulin sensitivity
- Exercise mimetic -- animal studies show MOTS-c injection produces metabolic adaptations similar to endurance exercise: increased fatty acid oxidation and improved mitochondrial efficiency
- Anti-inflammatory -- modulates inflammatory cytokine production, reducing chronic low-grade inflammation
The 2026 Research Landscape
MOTS-c is receiving significant research attention for metabolic syndrome, type 2 diabetes, and sarcopenia. Reviews of the field report that plasma MOTS-c declines with age.
Three findings since the original 2015 paper are worth knowing:
- It works at every age in mice. Treatment improved physical performance in mice aged 2, 12 and 22 months, and intermittent treatment begun late in life increased physical capacity and healthspan.
- A human gene variant points the same way. An Asian-specific mitochondrial DNA variant produces a less active MOTS-c (K14Q). Across three cohorts totalling 27,527 people, men carrying it had more type 2 diabetes — and in one cohort only those in the lowest third of physical activity.
- It improves mitochondrial efficiency, not quantity. 2026 work in mice found better muscle mitochondrial bioenergetics through PGC-1α and AMPK without a change in respiratory protein content.
What Has Not Been Shown
No published trial has administered MOTS-c to humans. The dosing above is a community convention extrapolated from animal work, not a trial-derived dose, and there are no human pharmacokinetic or safety data. In people, the intervention shown to raise MOTS-c is acute high-intensity exercise. Evidence grade C here reflects the human genetic and observational data alongside the animal work; for supplementation specifically, the evidence is preclinical.
MOTS-c is an AMPK activator, a class prohibited in tested sport.
Related Research
Stacking Interactions
How MOTS-c interacts with other compounds
Advanced metabolic stack. MOTS-c cycles 4-8 weeks; NMN daily. Use concurrently during active MOTS-c cycles.
Both activate AMPK through different mechanisms. Additive metabolic benefits. Monitor for hypoglycaemia.
The other well-characterised mitochondrial-derived peptide, encoded in the neighbouring 16S rRNA gene. Humanin is cytoprotective, MOTS-c metabolic. The combination has no study in any species, and humanin has no human dose.
The mitochondrial layer with human outcome trials. In the Mito-Peptide Advanced protocol CoQ10 runs from week 0 and MOTS-c is the optional experimental layer added later.
Protocols using MOTS-c
Evidence-graded stacks that include this compound
Safety Profile — Tier B
Generally safe — moderate evidence
Contraindications
- ●Pregnancy - insufficient safety data
- ●Active cancer - research ongoing
Side Effects
- ●Injection site reactions (subcutaneous)
- ●Mild fatigue in early days (metabolic adaptation)
- ●Long-term safety profile not yet established